Three years to a new name
The condition got renamed in May. What most coverage left out is the timetable: a three-year transition, an international guideline that doesn't formally adopt the new term until 2028, and records systems somewhere in between. Here is what actually changed on the day, and what is still years out.
Before anything else
Nothing here changes a diagnosis anyone already has. A name change is a change in terminology, not in what is wrong with you or what your clinician should do about it. If you have questions about your own records, ask the practice that holds them.
On 12 May, The Lancet published the outcome of a multistep global consensus process: polycystic ovary syndrome would be renamed polyendocrine metabolic ovarian syndrome. PMOS. We have been writing it as PMOS (PCOS) ever since, which looks clumsy and will keep looking clumsy for about three more years, for reasons this post is about.
The reasoning behind the change is not complicated, and it is not cosmetic. The old name pointed at the wrong organ and at a feature — cysts — that are not really cysts. The investigators' own summary of what they were fixing runs: Accuracy was improved by omitting cysts and by capturing endocrine, metabolic, and ovarian dysfunction.
That is the whole argument in one line.
Who asked for it
This is the part we did not expect. The renaming was not handed down by a committee of endocrinologists over the objections of patients. It was substantially driven by patients.
The consensus ran on Delphi surveys, workshops with clinicians and with women living with the condition, and formal implementation planning. Reported support was 86% among surveyed patients and 71% among health professionals. The American Society for Reproductive Medicine, one of 56 organisations involved, put it plainly in its own endorsement: women with the condition were the biggest drivers of the change.
Patients wanted it more than clinicians did — 86% against 71%. That gap is its own piece of information about who has been living with the consequences of the old name.
What they were reacting to is documented in the paper: a term that minimised the metabolic and systemic parts of the condition, and that participants connected to delayed diagnosis and fragmented care. If you have ever been told your ultrasound was clean and sent home, you already know the mechanism.
The timetable nobody put in a headline
Implementation is planned across a three-year transition. On the list of things to be updated: clinical guidelines, electronic health records, educational materials, the International Classification of Diseases systems, and future research publications. The International Guideline for the condition — the one in use across 195 countries — is expected to formally incorporate the new terminology in 2028.
So the practical position for the next while is a split one. The literature is moving to PMOS now. Your chart, your insurer's paperwork, your lab requisition and most intake forms will keep saying PCOS, because the coding systems underneath them are explicitly still on the to-do list. That is not anybody dragging their feet; it is what it takes to change a term embedded in a billing infrastructure.
What this means when you are choosing care
Three small, genuinely useful consequences.
Search both names. For the next several years, splitting your reading between the two terms will get you different results. Anything published before May 2026 — which is nearly all of it — is filed under the old one.
Don't read the old term as a red flag. A provider whose website still says PCOS in September 2026 is a provider whose website says what almost every website says. Terminology adoption is a poor proxy for clinical quality, and we would rather you judged a service on whether it orders a metabolic panel than on which acronym is in its meta description.
Do read the reasoning as a standard. The argument for the new name is that this is a multisystem endocrine and metabolic condition, not an ovarian one. That argument has a clinical shape: insulin, androgens, lipids, blood pressure, cardiometabolic risk over decades. A service that has absorbed the new name but still runs a weight-only intake has adopted the vocabulary without the content. That is the thing worth checking, and it is what the first row of every Care Standard scorecard is for.
Held carefully, as usual
The authors name their own limits: participation was lower from some low- and middle-income countries, and survey participation was voluntary, which invites selection bias — though they report naming preferences were broadly consistent across regions. A consensus process is a description of where a field has arrived, not a finding. It can be revisited.
And a new name does not treat anybody. It does not shorten a diagnostic delay by itself, it does not change what the trial evidence on GLP-1s does or doesn't show, and it does not put a lipid panel in front of a woman who has never been offered one. What it does is make the sentence "this is a metabolic condition" the default rather than the correction. For a condition that, on ASRM's figures, affects one in eight women — more than 170 million worldwide — that is a smaller thing than it sounds and a larger one than it looks.
The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a diagnosis, and not a recommendation about any medication. A change in terminology does not alter anyone's existing diagnosis or care plan; questions about your own records belong with the practice that holds them. No GLP-1 is FDA-approved specifically for PMOS (PCOS), and GLP-1 medications are not a treatment for endometriosis. Selene is editorial: we do not prescribe, sell, or dispense anything.
Sources. Teede HJ, Bahri Khomami M, Morman R, et al., "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process," The Lancet, published online 12 May 2026 (doi:10.1016/S0140-6736(26)00717-8); consensus method, support percentages, three-year implementation plan and the 2028 International Guideline date as reported by The American Journal of Managed Care, 13 May 2026. Endorsement, the 56-organisation figure and the one-in-eight prevalence estimate from the American Society for Reproductive Medicine, "PCOS is Now PMOS: Understanding the Name Change," 27 May 2026. Published summaries give differing totals for the number of survey responses collected during the consensus; we have cited the support percentages rather than the raw totals for that reason.